Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of VLA1553 chikungunya vaccine in adolescents
2026-000021-16Phase 3
- Sponsor
- Instituto Butantan
- Start
- Mar 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of chikungunya vaccine (live) in Chikungunya (CHIKV) (2 arms), sponsored by Instituto Butantan. Primary endpoint: Seroprotective CHIKV antibody response at Day 28.
02
Drugs
chikungunya vaccine (live)
03
Conditions
Chikungunya (CHIKV)
Beyond the preview
Go deeper on 2026-000021-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-000021-16.